Information That Can Help Define Treatment Options and Make Treatment Decisions for Breast and Colon Cancer Patients
About the Oncotype DX Breast Cancer Assay and Early Stage Breast CancerThe Oncotype DX breast cancer assay, is a test that examines a breast cancer patient's tumor tissue at a molecular level, and gives information about a patient's individual disease. This information can help individualize breast cancer treatment planning and identify options. The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The Oncotype DX gene expression assay is intended to be used by women with early-stage (stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy.
Oncotype DX Breast Cancer Assay Evaluation and Impacts on Breast Cancer Treatment OptionsThe Oncotype DX breast cancer multigene expression test has been extensively evaluated in 14 clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology.
Oncotype DX is the only test incorporated in published ASCO® and NCCN® breast cancer treatment guidelines for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For complete information on Oncotype DX for Patients & Caregivers, Healthcare Providers, and Managed Care Organizations, visit Oncotype DX.com.
For additional information for Patients & Caregivers and detail about breast cancer treatment options, visit MyBreastCancerTreatment.org. You may also watch a great, informative video at the address below.